Last reviewed · How we verify
NCT06775483
Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study
Phase 2 trial testing JSKN016 in Advanced Non-small Cell Lung Cancer in 220 participants. Not yet recruiting.
30 June 2027
Quick facts
| Lead sponsor | Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 17 January 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 November 2027 |
Drugs / interventions tested
- JSKN016
- Docetaxel (Docetaxel) — full drug profile →
Conditions studied
- Advanced Non-small Cell Lung Cancer — all drugs for Advanced Non-small Cell Lung Cancer →
Sponsor
Jiangsu Alphamab Biopharmaceuticals Co., Ltd — full company profile →
Who can join
18 and older, any sex, with Advanced Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase II clinical study conducted in China to evaluate the treatment of advanced non-small cell lung cancer with JSKN016. The enrolled subjects are all in the locally advanced or metastatic stage of non-small cell lung cancer.The study is divided into two parts. The main objective of part I is to assess the efficacy and safety of JSKN016 in selected subjects with advanced non-small cell lung cancer. The main objective of part II is to compare the efficacy of JSKN016 and docetaxel in subjects with advanced non-small cell lung cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06775483
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of JSKN016
Trials testing the same drug.
- NCT06942234 — Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer · Phase 1, PHASE2 · recruiting
- NCT06868732 — Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · Phase 1 · recruiting
Other recruiting trials for Advanced Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06868732 — Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC · Phase 1 · recruiting
- NCT06452277 — A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Particip · Phase 3 · recruiting
- NCT06269133 — Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non- · active not recruiting
- NCT06043973 — Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance · Phase 3 · recruiting
- NCT05416775 — Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer · Phase 1, PHASE2 · recruiting
Other Jiangsu Alphamab Biopharmaceuticals Co., Ltd trials
Trials by the same sponsor.
- NCT07533123 — A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who H · Phase 3 · recruiting
- NCT07391644 — A Study of JSKN027 in Patients With Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07475559 — JSKN016HC in Patients With Advanced or Metastatic Solid Malignant Tumors · Phase 1 · not yet recruiting
- NCT07283198 — A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients Wit · Phase 2 · not yet recruiting
- NCT07292402 — JSKN022 in Subjects With Advanced Malignant Solid Tumors · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06775483 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Last refreshed: 15 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06775483.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing